for Pharma

Diminish the hay stack...

… to find the needle faster. In-silico drug repurposing studies are a fast and efficient way to screen for new drug candidates to combat new or rare diseases. We also provide in-silico predictions of unexpected drug side effects before elaborated clinical trials for new drug discovery in the pharmaceutical and healthcare industries.

Looking beyond the surface

Protein-protein interactions are essential for understanding the behavioral processes of life, preventing disease, and developing new drugs. Despite developing high-throughput technologies to identify protein-protein interactions in large-scale biological experiments, these experiments are limited by time, cost, false-positive rate, and other conditions. Our CatalophoreTM Halo technology helps to create a more efficient workflow by optimising already existing processes or eliminating bottle necks.

Case study

Since the onset of the COVID-19 pandemic, we have been able to help shed more light on the nature of the SARS-CoV-2 virus through a series of studies.

Read more here.

In a recent structural bioinformatics approach, we gained new insights into the impact of amino acid exchanges on the affinity of the spike RBD for the human receptor hACE2.

Read more here: Structural bioinformatics analysis of SARS-CoV-2 variants reveals higher hACE2 receptor binding affinity for Omicron B.1.1.529 spike RBD compared to wild type reference
Durmaz, V., Köchl, K., Krassnigg, A. et al., Sci Rep 12, 14534 (2022).

Special problems require special solutions

Even though our platforms are ready-to-use, we do not believe in one-fits-all solutions. Tailor-made software solutions help you optimize your R&D pipeline and redefine how you solve problems. Our developers are committed to eliminating bottlenecks and adapting our CatalophoreTM platform to your needs. Our AI-driven technologies learn and grow with your projects and are customizable to your goals.